Welcome to our new website! Let us know what you think..

Register to get unlimited access to all of Citywire’s Fund Manager database. Registration is free and only takes a minute.

AstraZeneca rejects final £55 Pfizer offer

AstraZeneca rejects final £55 Pfizer offer

AstraZeneca has turned down a final offer for the company by rival Pfizer saying that the value of £55 per share ‘undervalues the company and its attractive prospects’.

At 8.45 shares in the business were down 14.17% at £41.39 - back where they stood before the bid was announced in April. 

Following a political row over the attempted buyout, Pfizer ruled out taking the bid hostile. The Labour party, which could be in power by the time any potential bid was finalised, has said it would consider a public interest test before offering regulatory approval. 

Following the rejection of the mixed cash and equity offer Astra chair Leif Johansson said: ‘Pfizer's approach throughout its pursuit of AstraZeneca appears to have been fundamentally driven by the corporate financial benefits to its shareholders of cost savings and tax minimisation.

‘From our first meeting in January to our latest discussion yesterday, and in the numerous phone calls in between, Pfizer has failed to make a compelling strategic, business or value case.

‘We have rejected Pfizer's final proposal because it is inadequate and would present significant risks for shareholders, while also having serious consequences for the company, our employees and the life-sciences sector in the UK, Sweden and the US.’

Pfizer had offered £53 per share after markets had closed on Friday. AstraZeneca indicated that it would not consider anything less than a 10% improvement pf those terms.

The company pointed to what it described as a ‘growing and accelerating’ number of drugs close to approval which it believes could have potential sales of up to $23 billion (£13.6 billion) a year.

Leave a comment
Citywire TV
Play BlackRock UK Special Sits: when will we sell our star holdings?

BlackRock UK Special Sits: when will we sell our star holdings?

What would prompt Roland Arnold to sell the likes of Ashtead and Howden?

Play AA-rated Lofthouse: 'maverick' tobacco settlements won't stop M&A

AA-rated Lofthouse: 'maverick' tobacco settlements won't stop M&A

Henderson International Income trust manager Ben Lofthouse shares his thoughts on recent developments in the tobacco sector in this video.

1 Play Renewable energy: what I found on my solar farm trip

Renewable energy: what I found on my solar farm trip

Renewable energy is attracting a lot of investor interest, so I headed to the UK's largest solar farm to find out more.

Your Business: Cover Star Club

Profile: how Matthew Butcher is carving a new role at Dart Capital

Profile: how Matthew Butcher is carving a new role at Dart Capital

The wealth management industry is undergoing a profound period of change: whether it wants to admit it or not.

Wealth Manager on Twitter